« Return to News | Drug Sponsors

Baxter acquires Gambro

Monday, September 9, 2013 03:49 PM

Baxter International has acquired Sweden-based Gambro, a privately-held global medical technology company and producer of dialysis products.

Baxter plans to accelerate product sales in established markets such as Europe, where Gambro has an extensive presence. Baxter also will expand Gambro's reach in high-growth regions of Latin America and Asia-Pacific, where Baxter has steadily grown its peritoneal dialysis (PD) business. In addition, Baxter will build upon its core portfolio and pipeline of investigational home hemodialysis (HD) and automated PD systems by adding Gambro's dialyzers, devices and dialysis solutions, next-generation monitors and acute therapies to treat patients with serious kidney, liver and lung conditions.

Brik Eyre has been named president of the combined renal business and has been elected a corporate officer of Baxter by the company's board of directors. He will report to Robert M. Davis, president of Baxter's medical products business. Eyre joined Baxter in 2008 and was general manager of U.S. medication delivery. Previously, Eyre was general manager for Baxter's biopharma solutions business.

The total cash consideration for the transaction was approximately $3.9 billion. The transaction was financed through a combination of cash generated from overseas operations and debt issuances.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.